DNA damage repair inhibitors for the treatment of cancer
US8071579B2 · kind B2 · utility
5Cited by
10References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 30, 2004 |
| Grant date | Dec 6, 2011 |
| Priority date | — |
| Expiry date | Aug 12, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.